What is 20n Bio?
20n Bio operates at the intersection of computational biology and high-throughput screening, specializing in the discovery of cyclic peptide therapeutics. By leveraging artificial intelligence to navigate complex biological landscapes, the company addresses the limitations of traditional small-molecule drugs. Its core focus on peptide drug conjugates and next-generation treatment platforms positions 20n Bio as a critical player in the development of targeted therapies for historically challenging disease states. The company's methodology integrates advanced data analytics with wet-lab validation, ensuring a robust pipeline of therapeutic candidates designed for high efficacy and specificity in clinical settings.
How much funding has 20n Bio raised?
20n Bio has raised a total of $10.8M across 1 funding round:
Seed
$10.8M
Seed (2026): $10.8M with participation from BlueRun Ventures China
Key Investors in 20n Bio
BlueRun Ventures China
A venture capital firm specializing in early-stage and growth-stage investments across the technology and healthcare sectors in the Chinese market.
What's next for 20n Bio?
Following this major strategic investment, 20n Bio is expected to scale its computational infrastructure and expand its laboratory capabilities to expedite the transition of its lead candidates into preclinical trials. The infusion of capital will likely support the expansion of its AI-driven discovery engine, allowing for a broader exploration of the peptide chemical space. As the company matures, the focus will shift toward establishing strategic partnerships with larger pharmaceutical entities to validate its platform at scale. This growth phase is critical for 20n Bio as it seeks to solidify its market position as a leader in the next wave of precision medicine, ultimately aiming to deliver transformative outcomes for patients with unmet medical needs.
See full 20n Bio company page
